| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |